Olanzapine and fluoxetine combination therapy for treatment-resistant depression: Review of efficacy, safety, and study design issues

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 369-383

  Bobo, William V ^a   Shelton, Richard C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Fluoxetine; Major depression; Olanzapine; Treatment resistance

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; LORAZEPAM; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HAMILTON SCALE; HUMAN; LOCUS CERULEUS; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NORADRENALIN BLOOD LEVEL; PROLACTIN BLOOD LEVEL; REMISSION; REVIEW; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 70449704967     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s5819     Document Type: Review

References (96)

1. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
2. Shelton RC. Treatment options for refractory depression. J Clin Psychiatry. 1999;60 Suppl 4:57-61.
3. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005 August; 25(4):336-341. (Pubitemid 41060253)
4. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22(9):1825-1837. (Pubitemid 44449239)
5. Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry. 2008;9(2):102-114.
6. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
8. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:26-31.
9. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry. 1998;44(5):348-360.
10. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739-752.
11. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 Suppl 13:23-29.
12. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.
13. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117(4):253-259. (Pubitemid 351350599)
14. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826-831. (Pubitemid 47015480)
15. Tyrka AR, Price LH, Mello MF, Mello AF, Carpenter LL. Psychotic major depression: a benefit-risk assessment of treatment options. Drug Saf. 2006;29(6):491-508.
16. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat. 2008;4(5):937-948.
17. Deeks ED, Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. Drugs. 2008;68(8):1115-1137. (Pubitemid 351693679)
18. Jans LA, Riedel WJ, Markus CR, Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry. 2007;12(6):522-543. (Pubitemid 46816766)
19. Schidkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509-522.
20. Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(3):435-451.
21. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003;64 Suppl 13:5-12. (Pubitemid 37267809)
22. Liotti M, Mayberg HS, McGinnis S, Brannan SL, Jerabek P. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry. 2002;159(11):1830-1840. (Pubitemid 35283247)
23. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156(5):675-682. (Pubitemid 29220063)
24. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol. 2002;12(6):527-544 (Pubitemid 35408704)
25. Marek G, Duman RS. Neural circuitry and signaling in depression. In: Kaplan GB, Hammer RP, editors. Brain Circuitry and Signaling in Psychiatry. Washington, DC: American Psychiatric Publishing, Inc.; 2002. p. 153-178.
26. Walsh ND, Williams SC, Brammer MJ, et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry. 2007 1;62(11):1236-1243. (Pubitemid 350060885)
27. Ishizaki J, Yamamoto H, Takahashi T, Takeda M, Yano M, Mimura M. Changes in regional cerebral blood flow following antidepressant treatment in late-life depression. Int J Geriatr Psychiatry. 2008;23(8):805-811.
28. Vlassenko A, Sheline YI, Fischer K, Mintun MA. Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. J Neuropsychiatry Clin Neurosci. 2004;16(3):360-363. (Pubitemid 39244564)
29. Davies J, Lloyd KR, Jones IK, Barnes A, Pilowsky LS. Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression. Am J Psychiatry. 2003;160(2):374-376. (Pubitemid 41110468)
30. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-258. (Pubitemid 28022649)
31. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994;114(4):559-565. (Pubitemid 24152135)
32. Rosenbaum JF, Tollefson GD. Fluoxetine. In: Schatzbert AF, Nemeroff CB, editors. Textbook of Psychopharmacology. Third Edition ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2004. p. 231-246.
33. Szabo ST, de MC, Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol. 1999;126(3):568-571.
34. Sodero AP, Valdomero A, Cuadra GR, Ramirez OA, Orsingher OA. Locus coeruleus activity in perinatally protein-deprived rats: effects of fluoxetine administration. Eur J Pharmacol. 2004;503(1-3):35-42. (Pubitemid 39445938)
35. West CH, Ritchie JC, Boss-Williams KA, Weiss JM. Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol. 2009;12(5):627-641.
36. Szabo ST, Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 2001;922(1):9-20. (Pubitemid 33152840)
37. Prisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol. 1995;116(2):1923-1931.
38. DiMascio M, DiGiovanni G, DiMatteo V, Prisco S, Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull. 1998;46(6):547-554. (Pubitemid 28409185)
39. DiGiovanni G, DeDeurwaerdere P, DiMascio M, DiMatteo V, Esposito E, Spampinato U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience. 1999;91(2):587-597. (Pubitemid 29193268)
40. DiMatteo V, DiGiovanni G, DiMascio M, Esposito E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology. 1999;38(8):1195-1205. (Pubitemid 29292408)
41. DiMatteo V, DiGiovanni G, DiMascio M, Esposito E. Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology. 1998;37(2):265-272. (Pubitemid 28293766)
42. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005;66 Suppl 8:30-40. (Pubitemid 43004173)
43. Seager MA, Huff KD, Barth VN, Phebus LA, Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry. 2004;55(11):1103-1109. (Pubitemid 38680563)
44. Gobert A, Rivet JM, Lejeune F, et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse. 2000;36(3):205-221. (Pubitemid 30252995)
45. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76(5):1521-1531. (Pubitemid 32198256)
46. Liegeois JF, Ichikawa J, Meltzer HY. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 2002;947(2):157-165. (Pubitemid 34899500)
47. Ichikawa J, Meltzer HY. R(+)-8-OH-DPAT, a serotonin (1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther. 1999;291(3):1227-1232.
48. Jentsch JD, Roth RH, Taylor JR. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action. Prog Brain Res. 2000;126:433-453.
49. Weisstaub NV, Zhou M, Lira A, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science. 2006;313(5786):536-540. (Pubitemid 44148461)
50. Feiger AD, Heiser JF, Shrivastava RK, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(3):243-249. (Pubitemid 36457321)
51. McGrath PJ, Stewart JW, Quitkin FM, et al. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol. 1994; 14(5):347-352. (Pubitemid 24316934)
52. Barde YA. Neurotrophins: a family of proteins supporting the survival of neurons. Prog Clin Biol Res. 1994;390:45-56.
53. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10(9):1089-1093. (Pubitemid 47339961)
54. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-1127.
55. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64(6):527-532.
56. Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol. 2007;7(1):18-21.
57. Luo C, Xu H, Li XM. Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res. 2004;1025(1-2):194-202. (Pubitemid 39349538)
58. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131-134. (Pubitemid 32047260)
59. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
60. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
61. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Guy W, ed . 1976. Rockville, MD, U.S. Department of Health, Education, and Welfare, DHEW Publication No. (ADM) 76-338.
62. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10):1289-1297.
63. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23(6):364-372. (Pubitemid 44619788)
64. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236. (Pubitemid 46362643)
65. Hamilton M. Hamiton Anxiety Scale. ECDEU Assessment Manual for Psychopharmacology, Guy W, ed, 193-198. 1976. Rockville, MD, U.S. Department of Health, Education, and Welfare.
66. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11 Suppl 3:89-95.
67. Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry. 2003;64(11):1349-1356. (Pubitemid 37490241)
68. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
69. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
70. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, 534-537. 1976. Rockville, MD, National Institute for Mental Health.
71. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853. (Pubitemid 47015482)
72. Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
73. Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat. 2008;4(1):11-21.
74. Daly EJ, Trivedi MH. A review of quetiapine in combination with antidepressant therapy in patients with depression. Neuropsychiatr Dis Treat. 2007;3(6):855-867.
75. Dodd S, Berk M. Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert Rev Neurother. 2008;8(9):1299-1306.
76. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry. 2009;70(3):387-396.
77. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088. (Pubitemid 37429647)
78. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67(7):1025-1033. (Pubitemid 44230872)
79. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2008 Dec 11:1-10. [Epub ahead of print]
80. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression - lack of manic induction. J Affect Disord. 2005;87(1):121-130. (Pubitemid 40828211)
81. Takahashi H, Kamata M, Yoshida K, Higuchi H, Ishigooka J. Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series. Hum Psychopharmacol. 2008;23(3):217-220. (Pubitemid 351577691)
82. Rasmussen K. Creating more effective antidepressants: clues from the clinic. Drug Discov Today. 2006;11(13-14):623-631. (Pubitemid 43912496)
83. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. (Pubitemid 29517559)
84. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
85. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1-93. (Pubitemid 40677047)
86. Iosifescu DV. Treating depression in the medically ill. Psychiatr Clin North Am. 2007;30(1):77-90.
87. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66(3):305-315. (Pubitemid 38668397)
88. Davidson KW, Kupfer DJ, Bigger JT, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med. 2006;68(5):645-650. (Pubitemid 44454630)
89. Frasure-Smith N, Lesperance F. Depression - a cardiac risk factor in search of a treatment. JAMA. 2003;289(23):3171-3173. (Pubitemid 37432895)
90. Hennekens CH. Prevention of premature mortality among patients with schizophrenia: the need for primary prevention efforts in cardiovascular disease. CNS Spectr 2008; 13(6 Suppl 10):9-10.
91. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147-156.
92. Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696-707. (Pubitemid 47422400)
93. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66 Suppl 8:5-12.
94. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003;53(8):743-753. (Pubitemid 39658488)
95. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 16:10-17.
96. Trivedi MH, Morris DW, Grannemann BD, Mahadi S. Symptom clusters as predictors of late response to antidepressant treatment. J Clin Psychiatry. 2005;66(8):1064-1070. (Pubitemid 41191801)